Anzeige
Mehr »
Login
Donnerstag, 14.11.2024 Börsentäglich über 12.000 News von 676 internationalen Medien
Investment in die Zukunft: Absoluter Geheimtipp - diese Aktie beschleunigt deine Renditechancen!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3EJH8 | ISIN: FR001400K4B1 | Ticker-Symbol: 2E40
München
14.11.24
08:16 Uhr
1,774 Euro
-0,002
-0,11 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
PHAXIAM THERAPEUTICS SA Chart 1 Jahr
5-Tage-Chart
PHAXIAM THERAPEUTICS SA 5-Tage-Chart
RealtimeGeldBriefZeit
1,6261,68021:37

Aktuelle News zur PHAXIAM THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiPhaxiam Therapeutics S.A.: PHAXIAM Reports Third-Quarter 2024 Financial Information153Cash and cash equivalents of €5.7 million as of September 30, 2024Execution of clinical strategy as planned, with the GLORIA global Phase II study initiation expected in the first quarter of 2025...
► Artikel lesen
FrPhaxiam Therapeutics S.A.: Monthly information related to total number of voting rights and shares composing the share capital - October 31, 20243
04.11.Phaxiam Therapeutics S.A.: PHAXIAM Therapeutics Receives FDA Clearance to Initiate Phase II GLORIA Study in the U.S.236GLORIA, the world's 1st phase II phage therapy study in the treatment of Prosthetic Joint Infections (PJI) related to Staphylococcus aureusThe clinical protocol also being submitted to the European...
► Artikel lesen
10.10.Phaxiam Therapeutics S.A.: Monthly information related to total number of voting rights and shares composing the share capital - October 8, 20241
PHAXIAM THERAPEUTICS Aktie jetzt für 0€ handeln
09.10.Phaxiam Therapeutics S.A.: PHAXIAM Therapeutics announces the validation of a new investigator-initiated phase 2 study348A Phase 2 study sponsored by Assistance Publique - Hôpitaux de Paris (AP-HP) as part of the hospital-based clinical research program (PHRC)Evaluation of the efficacy of a local treatment with PHAXIAM's...
► Artikel lesen
25.09.Phaxiam Therapeutics S.A.: PHAXIAM Provides Business and Financial Update For the First Half of 2024173Continuous commitment to create a global leader in phage therapies to treat severe and resistant bacterial infections Ambitious development strategy on track with clear objectives set for the Prosthetic...
► Artikel lesen
03.07.Phaxiam Therapeutics S.A.: Monthly information related to total number of voting rights and shares composing the share capital - July 1, 20243
28.06.Phaxiam Therapeutics S.A.: Results of the Combined General Meeting of 28 June 2024198Lyon (France) and Cambridge (MA, US), 28 June 2024 - 5.45 pm CEST - PHAXIAM Therapeutics (Euronext: PHXM; FR0011471135), a biopharmaceutical company developing innovative treatments for severe and...
► Artikel lesen
13.06.XFRA CAPITAL ADJUSTMENT INFORMATION - 13.06.2024347Das Instrument FA0 SE0007412374 PEXA AB SER.B EQUITY wird cum Kapitalmassnahme gehandelt am 13.06.2024 und ex Kapitalmassnahme am 14.06.2024 The instrument FA0 SE0007412374 PEXA AB SER.B EQUITY is traded...
► Artikel lesen
07.06.Phaxiam Therapeutics S.A.: PHAXIAM announces the availability of the preparatory documents for the Combined General Meeting of 28 June 20244
05.06.Phaxiam Therapeutics S.A.: Monthly information related to total number of voting rights and shares composing the share capital - May 31, 20244
15.05.Phaxiam Therapeutics S.A.: PHAXIAM provides Business and Financial Update for the First Quarter of 2024198PHAXIAM provides Business and Financial Update for the First Quarter of 2024 Webinar (in French) today, May 15, 2024, at 6.00 pm CEST Accelerated clinical efforts to roll-out PHAXIAM's strategy in...
► Artikel lesen
15.04.Phaxiam Therapeutics S.A.: PHAXIAM Therapeutics announces enrolment of the first patient in the phase 1 study for the treatment of endocarditis infections caused by Staphylococcus aureus266The study plans for the enrolment of 12 patients in 5 French clinical centersFirst study results expected in Q3 2024This study will enable an evaluation of the intravenous administration of phages,...
► Artikel lesen
05.04.Phaxiam Therapeutics S.A.: PHAXIAM Therapeutics announces filing of its 2023 Universal Registration Document (URD)323Lyon (France) and Cambridge (MA, US), 5 April 2024 - 6:00pm CEST - PHAXIAM Therapeutics (Euronext: PHXM; FR0011471135), a biopharmaceutical company developing innovative treatments for severe and...
► Artikel lesen
20.03.Phaxiam Therapeutics S.A.: PHAXIAM Announces 2023 Full-Year Results and Provides Business Update244Conference call and webcast (English) on Thursday, March 21, 2024 at 9:30am ET / 2:30pm CET Ongoing clinical efforts boding well to create a global phage-therapy leader in high-value indications First...
► Artikel lesen
11.03.Phaxiam Therapeutics S.A.: PHAXIAM Therapeutics announces effectiveness of voluntary delisting of American Depositary Shares from Nasdaq Stock Market648Lyon (France) and Cambridge (MA, US), March 11, 2024, at 07:00am CET - PHAXIAM Therapeutics (Nasdaq & Euronext: PHXM), a biopharmaceutical company developing innovative treatments for severe and...
► Artikel lesen
20.02.Phaxiam Therapeutics S.A.: PHAXIAM Therapeutics announces intention to voluntary delist American Depositary Shares from The Nasdaq Capital Market615PHAXIAM Therapeutics announces intention to voluntary delist American Depositary Shares from The Nasdaq Capital Market PHAXIAM remains listed on Euronext Paris as its primary trading marketNasdaq...
► Artikel lesen
18.01.Phaxiam Therapeutics S.A.: PHAXIAM Therapeutics announces its cash position at the end of 2023 and its financial calendar for 2024451Lyon (France) and Cambridge (MA, US), January 18, 2024, at 10:05pm CET - PHAXIAM Therapeutics (Nasdaq & Euronext: PHXM), a biopharmaceutical company developing innovative treatments for severe and...
► Artikel lesen
18 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1